β1-4 galactosylated glycan could inhibit SARS-CoV-2 infection

β1-4 galactosylated glycan could inhibit SARS-CoV-2 infection

A group from Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, Xi’an 710069, China has reported that β1-4 galactosylated glycan could inhibit SARS-CoV-2 infection.
https://www.sciencedirect.com/science/article/pii/S2090123224005666?via%3Dihub

It has been known that SARS-CoV-2-S protein has 22 potential N-glycosites and 17 O-glycosites, with 14 N-glycosites adorned with complex-type N-glycans, and ACE2 has a total of 7 N-glycosites, and most of these sites are occupied by complex-type N-glycans.

In this paper, it was demonstrated that the β1-4 galactosylated N-glycans of ACE2 play a crucial role as glycan receptors for the binding of S1 of SARS-CoV-2, and isolated glycoproteins harboring multivalent β1-4 galactosylated N-glycans exhibited the ability to competitively inhibit the interaction between S1 and ACE2, thereby preventing the attachment and entry of SARS-CoV-2 pseudovirus into host cells. This may be a rather late article, but let me introduce it to you.

Mx

Pioneer in Glycan Profiling Technology Environmentally Regenerative Agriculture

Comments are closed.

Powered by WordPress |Copyright © 2020 Emukk. All rights reserved